|
|
|
|
|
30.07.25 - 22:48
|
Countdown to the FOMC Decision | Bloomberg Markets 7/30/2025 (Bloomberg)
|
|
|
"Bloomberg Markets" follows the market moves across every global asset class and discusses the biggest issues for Wall Street. Today's guests; TCW CIO Bryan Whalen, LendingClub CEO Scott Sanborn, Stifel Chairman and CCEO Ron Kruszewski, Teva CEO Richard Francis, and JPMorgan Investment Management Fixed Income Executive Director Kelsey Berro. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.25 - 13:48
|
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025 (Business Wire)
|
|
|
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About UZEDY®
1-Month and 2-Month subcutaneous risperidone for schizophrenia
Commercialized in the U.S. since May 2023
sales: $117 million
Updated 2025 Revenue Outlook by Teva from ~$160 to $190 - $200 million
Q2 2025 sales $54 million, 2.2x increase compared to Q2 2024
H1 2025 sales $93 million, 2.3x increase compared to H1 2024
Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial milestones.
About Olanzapine Long-Acting Injectable (TEV-749 / mdc-TJK)
1-Month subcutaneous olanzapine, the most prescribed antipsychotic for schizophrenia in the U.S.
Pivotal Phase 3 completed in January 2025 with positive Phase 3 efficacy results1 and no PDSS2
Preparation for filing on track
Full maintenance efficacy and safety data planned for presentation in Q3 2025
NDA3 submission planned for Q4 2025
Following an...
|
|
|
|
|
|
|
29.07.25 - 15:51
|
TEVA Pharmaceutical Aktie: Nach wie vor ein sicherer Hafen? Kurszielsenkung vor Zahlen (Aktiencheck)
|
|
|
Minneapolis (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von Piper Sandler:
Piper Sandler habe in einer aktuellen Studie das Kursziel für die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN: US8816242098, WKN: 883035, Ticker-Symbol: TEV, NYSE-Symbol: TEVA) kurz vor Veröffentlichung der Quartalszahlen von 30 USD auf 29 USD gesenkt, das "overweight"-Rating jedoch bestätigt. [mehr]...
|
|
|
|
|
|
|
|
|
21.07.25 - 17:03
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships (Business Wire)
|
|
|
WHEELING, Ill.--(BUSINESS WIRE)--EdgeOne Medical, a professional service organization focused on device development service for combination products in the bio-pharmaceutical industry is pleased to announce the appointment of Mr. Michael Denzer as Vice President of Client Relations.
Michael brings over 30 years of extensive experience leading the development, commercialization, and lifecycle management of innovative packaging and combination products. His impressive track record spans a diverse range of drug delivery modalities, including respiratory products, small and large molecule injectables, and other advanced modes of administration that improve patient outcomes and enhance therapeutic efficacy.
Throughout his distinguished career, Mr. Denzer has held pivotal roles at leading pharmaceutical and biotech programs at companies including Schering-Plough (now Merck), Bristol Myers Squibb (BMS), Amgen, Otsuka, Shire, Teva, and most recently Civica. His deep industry knowledge and proven leadership have c...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
